Retatrutide, tested at 9 mg and 12 mg doses alongside diet and exercise, met all primary and key secondary endpoints
The investigational therapy uses SteadyTeq, a proprietary copolymer technology from Medincell designed to release olanzapine steadily over time
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
_256_384.jpg)
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
The study met its primary endpoint and all 11 secondary efficacy endpoints
HYMPAVZI’s safety profile was generally favorable
The launch of the study was on the occasion of the International Day of Persons with Disabilities
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development
MRI is particularly valuable in pediatric care due to its non-invasive nature
Subscribe To Our Newsletter & Stay Updated
